# Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema

> **NCT02712008** · PHASE2 · COMPLETED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 302 (actual)

## Conditions studied

- Diabetic Macular Edema

## Interventions

- **DRUG:** REGN910-3
- **DRUG:** Intravitreal Aflibercept Injection (IAI)

## Key facts

- **NCT ID:** NCT02712008
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03-02
- **Primary completion:** 2017-07-10
- **Final completion:** 2017-07-10
- **Target enrollment:** 302 (ACTUAL)
- **Last updated:** 2018-10-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02712008

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02712008, "Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02712008. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*